不同剂量辛伐他汀治疗老年高血压合并高脂血症的临床疗效及安全性探讨(1)
[摘要] 目的 探讨不同剂量辛伐他汀治疗老年高血压合并高脂血症的临床疗效及安全性。 方法 随机抽取该院于2016年9月—2018年10月期间到院就诊的老年高血压合并高脂血症患者共86例作为研究对象，按照辛伐他汀不同剂量的给药方案分配成参照组(20 mg辛伐他汀)、治疗组(30 mg辛伐他汀)，两组各分为43例，对所有患者治疗后的临床疗效及不良反应进行观察与评估，并予以分析和总结。 结果 通过治疗后发现，治疗组DBP(128.35±12.60)mmHg、SBP(84.73±9.36)mmHg、TC(3.90±1.61)mmol/L、TG(1.11±0.20)mmol/L、HDL-C(1.97±0.35)mmol/L、LDL-C(1.54±0.23)mmol/L血压、血脂各指标情况，均显著优于参照组DBP(143.52±10.07)mmHg、SBP(98.27±6.21)mmHg、TC(5.22±1.37)mmol/L、TG(1.93±0.27)mmol/L、HDL-C(3.41±0.53)mmol/L、LDL-C(1.04±0.13)mmol/L，差异有统计学意义(P<0.05);治疗组不良反应为2例(2.32%)，明显低于参照组的5例(11.63%)，差异有統计学意义(χ2=8.625，P<0.05);治疗组临床有效率42例(97.67%)，显著高于参照组的34例(79.07%)，差异有统计学意义(χ2=9.862，P<0.05)。 结论 采用30 mg辛伐他汀用于老年高血压合并高脂血症的治疗效果佳，且不良反应少，安全性高。
, http://www.100md.com
[关键词] 不同剂量;辛伐他汀;老年高血压;高脂血症;疗效;安全性
[中图分类号] R589.2;R544.1. [文献标识码] A [文章编号] 1674-0742(2019)08(b)-0111-03
[Abstract] Objective To investigate the clinical efficacy and safety of different doses of simvastatin in the treatment of hypertension and hyperlipidemia in the elderly. Methods A total of 86 elderly patients with hypertension and hyperlipidemia who were admitted to our hospital from September 2016 to October 2018 were enrolled in this study. The patients were assigned to the reference group according to the different doses of simvastatin (20 mg simvastatin)， treatment group (30 mg simvastatin)， the two groups were divided into 43 cases each， the clinical efficacy and adverse reactions of all patients after treatment were observed and evaluated， and analyzed and summarized. Results After treatment， DBP (128.35±12.60) mmHg， SBP (84.73±9.36) mmHg， TC (3.90±1.61) mmol/L， TG (1.11±0.20) mmol/L， HDL-C (1.97±0.35) mmol/L， LDL-C (1.54 ± 0.23) mmol/L blood pressure， blood lipids were found in the treatment group， all indicators were significantly better than the reference group DBP (143.52±10.07) mmHg， SBP (98.27±6.21) mmHg， TC (5.22±1.37) mmol/L， TG (1.93±0.27) mmol/L， HDL-C (3.41±0.53) mmol/L， LDL-C (1.04±0.13) mmol/L， the difference was statistically significant(P<0.05); the adverse reactions in the treatment group were 2 cases(2.32%)， which was significantly lower than the 5 cases(11.63%) of the reference group. The difference was statistically significant (χ2=8.625， P<0.05). The clinical effective rate of the treatment group 42 cases(97.67%)， significantly higher than the reference group of 34 cases (79.07%)， the difference was statistically significant (χ2=9.862， P<0.05). Conclusion 30 mg simvastatin is effective in the treatment of hypertension and hyperlipidemia in the elderly， with less adverse reactions and high safety., 百拇医药(林美萍)
, http://www.100md.com
[关键词] 不同剂量;辛伐他汀;老年高血压;高脂血症;疗效;安全性
[中图分类号] R589.2;R544.1. [文献标识码] A [文章编号] 1674-0742(2019)08(b)-0111-03
[Abstract] Objective To investigate the clinical efficacy and safety of different doses of simvastatin in the treatment of hypertension and hyperlipidemia in the elderly. Methods A total of 86 elderly patients with hypertension and hyperlipidemia who were admitted to our hospital from September 2016 to October 2018 were enrolled in this study. The patients were assigned to the reference group according to the different doses of simvastatin (20 mg simvastatin)， treatment group (30 mg simvastatin)， the two groups were divided into 43 cases each， the clinical efficacy and adverse reactions of all patients after treatment were observed and evaluated， and analyzed and summarized. Results After treatment， DBP (128.35±12.60) mmHg， SBP (84.73±9.36) mmHg， TC (3.90±1.61) mmol/L， TG (1.11±0.20) mmol/L， HDL-C (1.97±0.35) mmol/L， LDL-C (1.54 ± 0.23) mmol/L blood pressure， blood lipids were found in the treatment group， all indicators were significantly better than the reference group DBP (143.52±10.07) mmHg， SBP (98.27±6.21) mmHg， TC (5.22±1.37) mmol/L， TG (1.93±0.27) mmol/L， HDL-C (3.41±0.53) mmol/L， LDL-C (1.04±0.13) mmol/L， the difference was statistically significant(P<0.05); the adverse reactions in the treatment group were 2 cases(2.32%)， which was significantly lower than the 5 cases(11.63%) of the reference group. The difference was statistically significant (χ2=8.625， P<0.05). The clinical effective rate of the treatment group 42 cases(97.67%)， significantly higher than the reference group of 34 cases (79.07%)， the difference was statistically significant (χ2=9.862， P<0.05). Conclusion 30 mg simvastatin is effective in the treatment of hypertension and hyperlipidemia in the elderly， with less adverse reactions and high safety., 百拇医药(林美萍)